Biodesix, Inc. (NASDAQ:BDSX) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Biodesix, Inc. (NASDAQ:BDSX) have earned an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $32.50.

A number of brokerages recently issued reports on BDSX. Wall Street Zen upgraded Biodesix from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biodesix in a research note on Wednesday, October 8th. Finally, Canaccord Genuity Group set a $20.00 price target on shares of Biodesix and gave the company a “buy” rating in a research note on Friday, September 19th.

Biodesix Price Performance

Biodesix stock opened at $7.87 on Thursday. Biodesix has a 12 month low of $3.44 and a 12 month high of $32.20. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 41.11. The business’s 50 day simple moving average is $7.34 and its 200 day simple moving average is $7.14. The company has a market cap of $62.65 million, a price-to-earnings ratio of -1.42 and a beta of 0.98.

Biodesix (NASDAQ:BDSX) last released its earnings results on Monday, November 3rd. The company reported ($1.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.60) by $0.44. The business had revenue of $21.77 million during the quarter, compared to the consensus estimate of $20.98 million. Biodesix had a negative return on equity of 504.41% and a negative net margin of 49.31%. Biodesix has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Biodesix will post -0.35 EPS for the current year.

Insider Activity

In related news, Director Jack W. Schuler bought 142,045 shares of the company’s stock in a transaction on Friday, September 19th. The shares were purchased at an average price of $7.04 per share, for a total transaction of $999,996.80. Following the completion of the transaction, the director directly owned 1,380,745 shares in the company, valued at approximately $9,720,444.80. The trade was a 11.47% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last quarter, insiders acquired 334,836 shares of company stock worth $2,611,362 and sold 300 shares worth $2,286. 30.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Biodesix

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Millennium Management LLC purchased a new stake in Biodesix during the 3rd quarter worth about $113,000. Oracle Investment Management Inc. bought a new stake in shares of Biodesix during the third quarter valued at about $113,000. XTX Topco Ltd purchased a new stake in shares of Biodesix in the first quarter worth about $64,000. Blair William & Co. IL boosted its position in shares of Biodesix by 33.3% in the first quarter. Blair William & Co. IL now owns 124,100 shares of the company’s stock valued at $78,000 after acquiring an additional 31,000 shares during the period. Finally, Monashee Investment Management LLC boosted its position in shares of Biodesix by 15.7% in the first quarter. Monashee Investment Management LLC now owns 4,050,000 shares of the company’s stock valued at $2,532,000 after acquiring an additional 549,121 shares during the period. 20.96% of the stock is currently owned by institutional investors.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.